Can a cannabis compound calm autism irritability? new trial seeks answers
NCT ID NCT03202303
First seen Oct 31, 2025 · Last updated May 18, 2026 · Updated 29 times
Summary
This study tests whether cannabidivarin (CBDV), a non-psychoactive cannabis compound, can reduce irritability and repetitive behaviors in 100 children aged 5-18 with autism spectrum disorder. Participants receive either CBDV or a placebo, and parents report changes in behavior over time. The goal is to see if CBDV offers a safe, effective way to ease challenging symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
New York University (NYU) Langone
COMPLETEDNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.